Naveen Pemmaraju: Navitoclax and Ruxolitinib in Patients With Untreated Myelofibrosis

Naveen Pemmaraju shared a post on LinkedIn:

“A huge shout out to all of you for your continued congratulations & kudos from around the world to my colleagues, to my team, and to me, after my EHA2024 TRANSFORM-1 Navitoclax + RUXO vs RUXO+ Placebo showing a remarkable doubling of SVR35wk24 in the Navitoclax combination arm for JAKi-naive patients with intermediate-2/high risk Myelofibrosis, which was highly statistically significant, resulting in the sole primary endpoint being met, in this major international ph3 randomized double-blinded placebo-controlled oral presentation!!!”

Source: Naveen Pemmaraju/LinkedIn

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.